MetrioPharm Investor Relations News QI 2019
Greetings from Dr. Wolfgang Brysch, CEO of MetrioPharm AG
an important quarter has passed. We have successfully completed the recruitment of our Phase II clinical trial and were able to meet the set target number of patients. The conclusion of the treatment phase is now within reach and we are already preparing the evaluation of the collected data. The coming weeks and months will be busy and we are looking forward to the results for the treatment of psoriasis with MP1032.
Simultaneously, the expansion of our pipeline is progressing and our team is currently working on several new projects. You can find a more detailed report on this topic on our MetrioPharm Blog.
We are glad that you are with us in this exciting phase and on behalf of the entire team I wish you all the best and restful days for the upcoming Easter season.
Dr. Wolfgang Brysch
Chief Executive Officer
MetrioPharm in San Francisco, USA
From 07.-10.01.2018 the J.P. Morgen Healthcare Conference took place in San Francisco, USA. The conference is regarded one of the world's most important networking events in the pharmaceutical sector. Since there had already been great interest in meetings with MetrioPharm beforehand, Dr. Wolfgang Brysch, CEO, and Barry Frankel, Senior Vice President Strategy and Business Development, as well as Eva Brysch, Head of Investor Relations, and Felix Edler, Business Development, had travelled to the conference. During the meetings, the MetrioPharm team was able to establish important new contacts, both with institutional and private investors, as well as with potential pharmaceutical partners.
BIO CEO & Investor Conference, New York, USA
In February, Dr. Wolfgang Brysch, CEO, travelled to New York to represent MetrioPharm at the BIO CEO & Investor Conference. There, the CEOs of listed but also selected private biotech companies made presentations. Investors, industry analysts and biotechnology executives were able to get in direct contact. Dr. Wolfgang Brysch, CEO, and Barry Frankel, Senior Vice President Strategy and Business Development, took the opportunity to talk to potential investors at one-on-one meetings.
European Life Science CEO Forum
The 12th European Life Sciences CEO Forum (www.sachsforum.com) took place in Zurich on February 25 and 26. Dr. Wolfgang Brysch, CEO of MetrioPharm AG, was invited by the organizers to speak at the panel Autoimmune and Inflammatory Diseases. There was also the opportunity to explore licensing and partnering opportunities with regional and international pharmaceutical companies in one-on-one meetings.
Bio-Europe Spring, Vienna, Austria
The event is Europe's largest biotech partnering conference. This is where executives from biotechnology, pharmaceuticals and finance meet with up-and-coming companies every year. On March 26, Dr. Wolfgang Brysch, CEO, and Felix Edler, Business Development, travelled to Vienna for MetrioPharm to meet with selected potential pharmaceutical partners.
Corporate Calendar of MetrioPharm AG in QII 2019
April 11, 2019: J.P. Morgan Life Sciences - from San Francisco to Zurich, Zurich, Switzerland
At the exclusive event organized by J.P. Morgan, technology companies present themselves to selected investors. At the invitation of the organizers, Dr. Wolfgang Brysch, CEO, and Eva Brysch, Head of Investor Relations, will be presenting MetrioPharm AG.
June 03 - 06, 2019: BIO International Conference, Philadelphia, USA
The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO). It is the world's largest event for the biotechnology industry, attracting many big names in the healthcare sector and providing important networking and partnering opportunities. MetrioPharm will be represented by Dr. Wolfgang Brysch, CEO, Barry Frankel, Senior Vice President Strategy and Business Development, and Felix Edler, Business Development.
June 18, 2019: Annual General Meeting of MetrioPharm AG, Zurich, Switzerland
The Annual General Meeting of MetrioPharm AG is scheduled to take place on June 18, 2019 in Zurich. We look forward to seeing you in large numbers. You will receive an invitation to the Annual General Meeting with the scheduled topics separately by post, provided that your shares are entered in our share register.
Please note that our shares are registered shares. This means that you may only exercise your voting rights if your shares are entered in our share register in your name or in the name of a proxy. If you are not sure whether your shares are registered, ask your bank or MetrioPharm at email@example.com. Please also check whether the number of registered shares is correct.
Should further dates be added for the next quarter, you can find out more on our website at www.metriopharm.com.
Head of Investor Relations & Corporate Communications